<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Zapatero, Almudena</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">LTAD Improved Outcomes in Prostate Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Previous study findings support that overall survival is improved with hormone therapy and conventional-dose radiotherapy in patients with intermediate and high-risk prostate cancer and that biochemical outcomes as well as clinical outcomes were improved with dose-escalated radiotherapy. This article discusses the findings of a phase 3 trial that compared long-term androgen deprivation therapy with short-term androgen deprivation therapy in patients with intermediate and high-risk localized prostate cancer treated with high-dose radiotherapy.</style></abstract><number><style face="normal" font="default" size="100%">31</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>